EFFECT OF SACUBITRIL/VALSARTAN VS. ENALAPRIL ON CHANGES IN BACKGROUND MEDICAL THERAPY OVER TIME IN THE PARADIGM-HF TRIAL

被引：0
|
作者：
Bhatt, Ankeet [1 ]
Vaduganathan, Muthiah [1 ]
Claggett, Brian [1 ]
Liu, Jiankang [1 ]
Packer, Milton [1 ]
Desai, Akshay S. [1 ]
Lefkowitz, Martin [1 ]
Rouleau, Jean L. [1 ]
Shi, Victor [1 ]
Zile, Michael [1 ]
Swedberg, Karl [1 ]
Vardeny, Orly [1 ]
McMurray, John [1 ]
Solomon, Scott D. [1 ]
机构：
[1] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2020年 / 75卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1415-117
引用
收藏
页码：1002 / 1002
页数：1
相关论文
共 50 条
  • [21] B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan The PARADIGM-HF Trial
    Myhre, Peder Langeland
    Vaduganathan, Muthiah
    Claggett, Brian
    Packer, Milton
    Desai, Akshay S.
    Rouleau, Jean L.
    Zile, Michael R.
    Swedberg, Karl
    Lefkowitz, Martin
    Shi, Victor
    McMurray, John J. V.
    Solomon, Scott D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (11) : 1264 - 1272
  • [22] Asymptomatic vs Symptomatic Hypotension With Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction in PARADIGM-HF
    Matsumoto, Shingo
    Shen, Li
    Henderson, Alasdair D.
    Boehm, Michael
    Desai, Akshay S.
    Kober, Lars
    Lefkowitz, Martin P.
    Packer, Milton
    Rouleau, Jean L.
    Solomon, Scott D.
    Swedberg, Karl
    Vaduganathan, Muthiah
    Vardeny, Orly
    Voors, Adriaan A.
    Zile, Michael R.
    Jhund, Pardeep S.
    McMurray, John J., V
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 84 (18) : 1685 - 1700
  • [23] Prognostic importance of heart rate, and effect of sacubitril/valsartan according to heart rate, in PARADIGM-HF
    Castagno, D.
    Jhund, P.
    Rouleau, J. L.
    Swedberg, K.
    Zile, M. R.
    Lefkowitz, M. P.
    Shi, V. C.
    Solomon, S. D.
    Packer, M.
    Mcmurray, J. J. V.
    EUROPEAN JOURNAL OF HEART FAILURE, 2016, 18 : 120 - 121
  • [24] Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy
    Okumura, Naoki
    Jhund, Pardeep S.
    Gong, Jianjian
    Lefkowitz, Martin P.
    Rizkala, Adel R.
    Rouleau, Jean L.
    Shi, Victor C.
    Swedberg, Karl
    Zile, Michael R.
    Solomon, Scott D.
    Packer, Milton
    McMurray, John J. V.
    CIRCULATION-HEART FAILURE, 2016, 9 (09)
  • [25] The clinical profile of a non-selected population treated with sacubitril/valsartan is different from PARADIGM-HF trial
    Vicent Alaminos, L. Lourdes
    Esteban Fernandez, A.
    Gomez Bueno, M.
    De Juan, J.
    Diez Villanueva, P.
    Iniesta, A. M.
    Ayesta, A.
    Gonzalez Saldivar, H.
    Rojas, A.
    Bover Freire, R.
    Iglesias, D.
    Garcia Aguado, M.
    Perea Egido, J. A.
    Martinez-Selles, M.
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 9 - 9
  • [26] Generalizability Of The Paradigm-HF Trial For The Use Of Sacubitril/Valsartan In A Tertiary Care Outpatient Heart Failure Patient Population
    Sackheim, Julia
    Chan, Doris
    Beers, Kelly
    Khan, Hassan
    Papadimitriou, Lampros
    Bloom, Michelle W.
    Butler, Javed
    Skopicki, Hal
    CIRCULATION, 2016, 134
  • [27] Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan
    Sokos, George G.
    Raina, Amresh
    VASCULAR HEALTH AND RISK MANAGEMENT, 2020, 16 : 41 - 51
  • [28] Sacubitril-valsartan in patients with NT-proBNP levels outrange of PARADIGM-HF trial inclusion criteria
    Mario Galvan Ruiz, M.
    Fernandez De Sanmamed Giron, M.
    Singh, M.
    Groba Marco, M. V.
    Davila Ramos, M.
    Lopez Perez, M.
    Hernandez Meneses, B.
    Godoy Camacho, C.
    Martin Lorenzo, P.
    Cardenes Leon, A.
    Bujanda Morun, P.
    Perez Nogales, E. D.
    Medina Gil, J. M.
    Caballero Dorta, E.
    Garcia Quintana, A.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 112 - 113
  • [29] Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril A Secondary Analysis of the PARADIGM-HF Trial
    Desai, Akshay S.
    Vardeny, Orly
    Claggett, Brian
    McMurray, John J. V.
    Packer, Milton
    Swedberg, Karl
    Rouleau, Jean L.
    Zile, Michael R.
    Lefkowitz, Martin
    Shi, Victor
    Solomon, Scott D.
    JAMA CARDIOLOGY, 2017, 2 (01) : 79 - 85
  • [30] Sacubitril/valsartan: from the PARADIGM-HF trial results to heart failure patients in internal medicine. A narrative review
    Verdiani, Valerio
    ITALIAN JOURNAL OF MEDICINE, 2021, 15 (01) : 17 - 26
12345